CNTA - Centessa Pharma get FDA nod to begin trial of solid tumors treatment

• Centessa Pharma ( NASDAQ: CNTA ) said it had received clearance for Investigational New Drug application from the U.S. Food and Drug Administration to start a Phase 1/2a trial of LB101 for the treatment of solid tumors.
• LB101, monoclonal antibody targeting solid tumors, is the first product candidate developed using the company’s LockBody technology which is designed to selectively drive potent effector function activity, such as CD47, in the tumor microenvironment ( TME ) while avoiding systemic toxicity.
• ( CNTA ) is trading ~2% higher .

For further details see: